LOCALLY ADVANCED RECTAL CANCER

This phase 2 trial will test whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy (capecitabine and oxaliplatin) can completely eliminate tumors in patients with locally advanced rectal cancer before surgery. The study plans…

This phase 2 trial is testing a new approach for people with a certain type of locally advanced rectal cancer. The treatment combines short-course radiation (sparing lymph nodes), two chemotherapy drugs (capecitabine and oxaliplatin), and an immunotherapy drug (sintilimab). The g…

This study tests whether adding the immunotherapy drug camrelizumab to standard chemoradiotherapy can make rectal tumors disappear completely in people with a common type of locally advanced rectal cancer. About 44 adults aged 18-75 with tumors within 10 cm of the anus will recei…

This study tests whether adding radiotherapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (Toripalimab) can improve outcomes for people with a specific type of locally advanced rectal cancer (MSS/pMMR). About 192 participants will receive either the drug com…

This early-phase trial is testing whether giving chemotherapy first, followed by a higher-than-usual dose of MRI-guided radiation, can eliminate tumors in people with locally advanced rectal cancer. The goal is to see if this approach is safe and can lead to a complete response, …

This study compares two standard treatment approaches for older adults (age 70+) with locally advanced rectal cancer. The goal is to see which approach helps people live longer and with fewer side effects. About 230 participants will be randomly assigned to receive either convent…

This phase II trial tests whether adding an immunotherapy drug (serplulimab) and a COX-2 inhibitor (celecoxib) to standard chemoradiotherapy can improve outcomes for people with locally advanced rectal cancer. 138 participants will receive either long-course or short-course radia…

This study is testing a jelly-based nutritional supplement in 52 people with head and neck, lung, or rectal cancer who are receiving standard cancer treatments like chemo or radiation. The supplement contains ingredients like arginine, omega-3, and olive oil, and is taken twice d…

This study follows 110 adults with head and neck, lung, or rectal cancer to see how their nutrition and body composition change during standard cancer treatments. Researchers will measure food intake, muscle mass, and strength over time. The goal is to gather data that could late…

This observational study is developing a model that combines MRI scans, blood tests, and tissue samples to predict whether rectal cancer patients achieve a complete response after neoadjuvant therapy. Researchers will enroll 106 patients with locally advanced rectal cancer and co…